SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Annual Trading Update

8 Oct 2009 07:00

RNS Number : 4270A
Victrex PLC
08 October 2009
 



Thursday 8 October 2009

Victrex plc

Annual Trading Update

Victrex will announce its results for the year ended 30 September 2009 on Tuesday 8 December 2009. Today, the Company announces its regular annual trading update. 

Invibio

Invibio®, our biomaterials division, had an excellent year with revenue of approximately £34.1m, an increase of 37% over the previous year (£24.9m). At £16.5m, second half revenue was down 6% on the very strong first half (£17.6m) principally as a result of inventory rationalisation at certain customers.

 

Group sales volume

Encouragingly, monthly volumes have shown continued improvement throughout the second half due to increased Victrex Polymer Solutions sales. Following the low point of 88 tonnes in March, as previously announced, Group volume recovered to 110 tonnes in April, with a further increase to 142 tonnes in July. This level was sustained in August with a further increase to approximately 155 tonnes in September. Group sales volume for the year is therefore expected to be approximately 1,545 tonnes.

As a result of the sales volume achieved in the fourth quarter, whave increased polymer production levels and have recommenced monomer production.

Outlook

Overall, we expect profits for 2009 to be in line with market expectations.

Invibio continues to show strong sales performance and development potential. Accordingly, we expect further revenue growth in 2010.

While it is still too early to judge the extent to which the recovery in Victrex Polymer Solutions sales volume in the second half of 2009 is due to restocking or a higher level of sustainable demand, it represents a positive trend. However2010 sales volume will be highly dependent on the extent to which this recovery is sustained.

-Ends-

Enquiries

Victrex plc

Mike Peacock, Finance Director 01253 897700 

Hogarth Partnership Limited

Nick Denton / Barnaby Fry 0207 357 9477

Victrex plc is an innovative world leader in high performance materials through the manufacture of VICTREX® PEEK™ polymer, a high performance, easy to process thermoplastic.

With over 30 years of experience, Victrex is a global manufacturer of innovative, high performance thermoplastic polymers. The Victrex Polymer Solutions Division ('VPS') is responsible for polymer business in our major industrial markets including transport, energy and electronics. The Biomaterials Solutions Division ('Invibio') provides specialist solutions for medical device manufacturers.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTCKOKQABDDQKK
Date   Source Headline
29th May 202611:00 amRNSTotal Voting Rights
18th May 20268:50 amRNSDirectorate change
11th May 20267:00 amRNSHalf-year Financial Report
30th Apr 202610:46 amRNSTotal Voting Rights
29th Apr 20264:28 pmRNSHolding(s) in Company
31st Mar 20261:37 pmRNSTotal Voting Rights
24th Mar 20264:29 pmRNSHolding(s) in Company
24th Mar 20262:03 pmRNSHolding(s) in Company
20th Mar 20269:38 amRNSHolding(s) in Company
27th Feb 20262:40 pmRNSTotal Voting Rights
27th Feb 20261:02 pmRNSHolding(s) in Company
24th Feb 202611:41 amRNSHolding(s) in Company
17th Feb 20263:06 pmRNSDirector/PDMR Shareholding
12th Feb 20263:26 pmRNSDirector/PDMR Shareholding
12th Feb 20263:22 pmRNSDirector/PDMR Shareholding
10th Feb 20262:43 pmRNSDirector/PDMR Shareholding
10th Feb 20269:00 amRNSDirectorate change
6th Feb 20261:33 pmRNSResult of AGM
6th Feb 20267:00 amRNSQ1 Trading Update
30th Jan 202611:49 amRNSTotal Voting Rights
28th Jan 202612:25 pmRNSHolding(s) in Company
22nd Jan 202610:21 amRNSHolding(s) in Company
20th Jan 20261:26 pmRNSAdditional Listing
31st Dec 20259:00 amRNSTotal Voting Rights
31st Dec 20259:00 amRNSTotal Voting Rights
22nd Dec 202512:00 pmRNSAnnual Financial Report
22nd Dec 202512:00 pmRNSAnnual Financial Report
18th Dec 202511:49 amRNSDirector/PDMR Shareholding - Replacement
17th Dec 20253:42 pmRNSDirector/PDMR Shareholding
17th Dec 202512:08 pmRNSDirector/PDMR Shareholding
15th Dec 20259:00 amRNSDirector/PDMR Shareholding
11th Dec 20258:52 amRNSDirector/PDMR Shareholding
5th Dec 20259:30 amRNSShare purchase by incoming Director (incoming CEO)
4th Dec 20259:06 amRNSFinancial Calendar Update
2nd Dec 20257:00 amRNSPreliminary Results
1st Dec 202510:49 amRNSBlock listing Interim Review
28th Nov 20259:27 amRNSTotal Voting Rights
20th Nov 20259:05 amRNSAdditional Listing
7th Nov 202510:39 amRNSHolding(s) in Company
31st Oct 20258:58 amRNSTotal Voting Rights
21st Oct 20257:30 amRNSCEO Succession update
3rd Oct 202511:36 amRNSHolding(s) in Company
3rd Oct 20259:03 amRNSHolding(s) in Company
30th Sep 20259:54 amRNSTotal Voting Rights
29th Aug 202510:16 amRNSTotal Voting Rights
31st Jul 20259:14 amRNSTotal Voting Rights
9th Jul 20251:02 pmRNSHolding(s) in Company
8th Jul 20253:33 pmRNSDirector/PDMR Shareholding
8th Jul 20257:00 amRNSDirectorate change: CEO succession
8th Jul 20257:00 amRNSQ3 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.